Rationale and design of the ESC Heart Failure III Registry - Implementation and discovery.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lund Lars H, Crespo-Leiro Maria Generosa, Laroche Cecile, Garcia-Pinilla Jose M, Bennis Ahmed, Vataman Eleonora B, Polovina Marija, Radovanovic Slavica, Apostolovic Svetlana R, Ašanin Milika, Gackowski Andrzej, Kaplon-Cieslicka Agnieszka, Cabac-Pogorevici Irina, Anker Stefan D, Chioncel Ovidiu, Coats Andrew J S, Filippatos Gerasimos, Lainscak Mitja, Mcdonagh Theresa, Mebazaa Alexandre, Metra Marco, Piepoli Massimo, Rosano Giuseppe M, Ruschitzka Frank, Savarese Gianluigi, Seferović Petar M, Iung Bernard, Popescu Bogdan A, Maggioni Aldo P, ESC EORP HF III National Leaders and Investigators
Аннотация
METHODS: Between 1 November 2018 and 31 December 2020, 10 162 patients with chronic or acute/worsening HF with reduced, mildly reduced, or preserved ejection fraction were enrolled from 220 centres in 41 European or ESC affiliated countries. The ESC HF III Registry collected data on baseline characteristics (hospital or clinic presentation), hospital course, diagnostic and therapeutic decisions in hospital and at the clinic visit; and on outcomes at 12-month follow-up. These data include demographics, medical history, physical examination, biomarkers and imaging, quality of life, treatments, and interventions - including drug doses and reasons for non-use, and cause-specific outcomes.
CONCLUSION: The ESC HF III Registry will provide comprehensive and unique insight into contemporary HF characteristics, treatment implementation, and outcomes, and may impact implementation strategies, clinical discovery, trial design, and public policy.